ロード中...
Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab
BACKGROUND: The safety of pembrolizumab monotherapy in treatment‐naïve non‐small cell lung cancer (NSCLC) patients with high programed death‐ligand 1 (PD‐L1) expression and pre‐existing interstitial lung disease (ILD) has not yet been determined. Here, we aimed to evaluate the prognosis, efficacy an...
保存先:
| 出版年: | Thorac Cancer |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons Australia, Ltd
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7862785/ https://ncbi.nlm.nih.gov/pubmed/33185333 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13725 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|